Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech
Gilead’s dealmaking spree, part of biopharma’s “blistering” M&A this year, continued on Tuesday with a consummation of oncology and inflammation startup XinThera.
After deals for UK startup MiroBio, a Jounce antibody and Tmunity — while passing on Pionyr — Gilead is now further expanding beyond its HIV products with a biotech nearing the clinic with two oral small molecule PARP1 inhibitors for various tumors. Part of the DNA-repairing enzyme family, PARP is targeted by the likes of AstraZeneca’s Lynparza and GSK and Tesaro’s Zejula, but dose-limiting toxicities limit their use. Merck KGaA, Duke Street Bio and others are interested in next-gen moves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.